Talking Medicines, the world’s first social intelligence company for the pharmaceutical industry, is gearing up for growth in 2021 with three senior appointments.
Tatiana Nantes joins the team as Head of Product from VMware, bringing 10 years of international agile product management experience to the award-winning scale-up. In the newly created role, Tatiana will be responsible for the delivery of social intelligence solutions for the pharmaceutical industry.
Also joining the team is Tom Lynch as Senior Engineer and Adrian Mursec as Frontend Developer.
Tom is a software engineer based in London with a background in consultancy and broad experience in data science, analytics and data engineering, having built and maintained big data pipelines in the cloud for clients in retail, energy and insurance sectors.
Adrian is a Frontend developer based in Manchester with 15 years’ experience of has working with startups, agencies and large tech companies.
The latest hires follow a £1.1 million funding deal led by Tern PLC, secured in November 2020, to scale up Talking Medicine’s AI-based data technology platform to track patient experience for the pharmaceutical industry. Following the investment by Tern, Al Sisto joined the board of Talking Medicines as Chairman.
As well as taking on new staff this year, Talking Medicines is using the funds to support the launch and roll-out of a new AI data platform, which provides social intelligence insights for the world’s leading drug brands, delivering more effective marketing and better health outcomes for patients
Talking Medicines CEO, Jo Halliday, said: “2021 is a huge year for Talking Medicines. Having been in a deep R&D stage developing our AI offering, we are now in a great position to launch our platform to the pharma industry and realise our ambition of supporting pharma to deliver more effective drug marketing and, ultimately, better health outcomes for patients. Tatiana, Tom and Adrian will all provide invaluable expertise and experience as we embark on this next phase of growth with a view to securing Series A funding later this year.”
Tatiana Nantes said, “Having been introduced to the world of tech shortly after leaving University, ever since I have been part of building products that are used by millions of people around the world in companies such as Time Out, Momondo and VMware.
I’m really excited to be joining the team at Talking Medicines at such an important stage in its development. The opportunity to play a crucial role in helping to launch and develop a world-class data solution while also delivering a significant social impact was too good to miss.”
About Talking Medicines
Talking Medicines, based in Glasgow and London, uses advanced data science techniques to provide pharmaceutical companies with real-time data intelligence. The company uses a collection of AI, ML and NLP tech tools to capture and structure the global digital voice of the patient from real world conversations and behaviours at home. Through mapping the patient voice from social media and connected devices to regulated medicine information, Talking Medicines is able to build data points to determine trends and patterns of patient sentiment across medicines. Pharmaceutical companies are able to use these metrics to support patient centric marketing decisions, driving more effective medicines and marketing spend.